As­traZeneca's Farx­i­ga gets rough FDA re­view date for ground­break­ing move in­to chron­ic kid­ney dis­ease

As­traZeneca’s Farx­i­ga broke ground last year with an FDA nod for heart fail­ure pa­tients with or with­out type 2 di­a­betes — a first-in-class ap­proval. But Farx­i­ga …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER